Epicardial fat CT in patients after heart attack
Official title: Epicardial Cardiac Fat Comparative Trial
Run by Instituto Mexicano del Seguro Social · NCT07297589 · Data updated 2026-11-12
This trial will test whether dapagliflozin or semaglutide reduces epicardial (around-the-heart) fat over 12 months in adults hospitalized with ST-elevation or non‑ST‑elevation myocardial infarction.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 136 (estimated) |
| Sponsor | Instituto Mexicano del Seguro Social Government |
| Locations | 1 site (León, Guanajuato) |
| Status | Recruiting |
| Started | December 30, 2025 |
| Main results expected | January 2027 |
| Study ends | March 2027 |
| Registry record updated | January 2, 2026 |
| Trial ID | NCT07297589 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults hospitalized with STEMI or NSTEMI who are clinically obese (often with elevated hs‑CRP), have preserved LVEF, and can start and tolerate either dapagliflozin or semaglutide are the intended candidates.
✕Probably not a fit
Patients who are pregnant, hemodynamically unstable, have active infections, cancer, pancreatitis, recent immunosuppression, a prior history of ischemic heart disease, or recent long-term use of the study drugs are excluded and unlikely to benefit from enrollment.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, open-label Phase 3 comparison of dapagliflozin 10 mg versus oral semaglutide (Rybelsus) given for 12 months. Epicardial fat volume will be measured by coronary CT during the initial hospitalization for infarction and again at 12 months. The trial enrolls adults with STEMI or NSTEMI who meet the protocol's clinical and laboratory criteria, and patients receive standard post‑MI care while adherence and tolerability are monitored. Key exclusions include recent immunosuppression, active infection, cancer, pancreatitis, hemodynamic instability, pregnancy, and prior long-term use of the study drugs.
Why it matters
Potential benefit: If successful, one or both drugs could reduce epicardial fat and potentially lower the risk of future ischemic cardiac events after myocardial infarction.
How similar studies have gone: Large outcome trials have shown cardiovascular benefits for SGLT2 inhibitors and GLP‑1 receptor agonists and smaller imaging studies report reductions in visceral and epicardial fat, but direct head‑to‑head post‑MI comparisons are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Criteria for the fourth definition of acute myocardial infarction with and without ST-segment elevation. * Diagnosed with type 2 diabetes. * Initial serum high-sensitivity CRP value \> 2.0 mg/L. * Clinically obese. * LVEF \>50%. Exclusion Criteria: * Patients who have recently received immunosuppressive therapy * Patients with a history of ischemic heart disease * Known allergy to any of the medications used * Use of any of the study drugs more than 6 months prior to randomization * Patients experiencing diabetic ketoacidosis * Patients with hemodynamic instability (mean arterial pressure \<60 mmHg while on vasopressors) * Pregnant women * Patients with a history or current diagnosis of cancer * Patients with documented active infections, such as pneumonia or urinary tract infections * Patients with pancreatitis
Where it's running
-
Unidad Medica de Alta Especialidad No. 1, Bajío
León, Guanajuato, Mexico Recruiting
Study contacts
- Study coordinator: Hilda Elizabeth Macías-Cervantes, Ph.D.
- Email: hildamacer@gmail.com
- Phone: 4777174800
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Noninvasive Venous Stasis to Help Reperfuse the Heart in STEMI
This study tests whether briefly restricting venous return with a cuff before the usual heart attack treatment helps restore blood flow on its own.
-
Sustained thrombectomy plus PCI versus PCI alone in high thrombus burden STEMI
This trial tests whether adding sustained mechanical thrombectomy to PCI helps patients with STEMI and large clot burden, compared to PCI alone.
-
Antithrombotic options for acute coronary syndrome with coronary artery ectasia
This trial tests whether using rivaroxaban instead of the usual aspirin plus clopidogrel better prevents clot-related complications in adults hospitalized with acute coronary syndrome who have coronary artery ectasia.
-
Prehospital pulse-dose methylprednisolone for ST-elevation myocardial infarction
We will test if a single high dose of methylprednisolone given before hospital arrival can reduce heart muscle damage in adults having an ST-elevation heart attack.
-
AI-guided early thrombolysis for people with STEMI
This trial tests whether an AI-assisted mobile app can help clinicians give earlier thrombolysis (plus planned PCI) for adults with STEMI who are unlikely to have the lesion opened within 120 minutes.
-
Registry evaluating SuperSaturated Oxygen Therapy for heart attack treatment
This study is testing whether SuperSaturated Oxygen Therapy can help people who have had a heart attack feel better compared to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.